Eighty men with a clinical suspicion of prostate cancer (PCa) were enrolled as a part of IMRPOD trial (NCT01864135). The performance of 9 clinical parameters, 11 mRNA transcript levels and 4 IMPROD biparametric MRI (bpMRI) parameters for detection of PCa with Gleason score ≥3+4 was evaluated using GreedyRLS feature selection and nested cross-validation with area under the curve obtained from tournament leave-pair-out cross validation. IMPROD bpMRI reported using qualitative IMPROD Likert scoring system demonstrated high accuracy for PCa detection and none of the remaining parameters led to further improvement. All data are freely are available at the following address: http://petiv.utu.fi/improd
This abstract and the presentation materials are available to members only; a login is required.